197 related articles for article (PubMed ID: 36432693)
21. Potential Role of Xylitol Plus Grapefruit Seed Extract Nasal Spray Solution in COVID-19: Case Series.
Go CC; Pandav K; Sanchez-Gonzalez MA; Ferrer G
Cureus; 2020 Nov; 12(11):e11315. PubMed ID: 33173650
[TBL] [Abstract][Full Text] [Related]
22. Characteristics of patients affecting the duration of positivity at SARS-CoV-2: a cohort analysis of the first wave of epidemic in Italy.
Milani L; Cigliano F; Catalano A; Macciotta A; Viola M; Caramello V; Costa G; Ricceri F; Sacerdote C
Epidemiol Prev; 2021; 45(6):533-542. PubMed ID: 35001598
[TBL] [Abstract][Full Text] [Related]
23. Effect of the povidone iodine, hypertonic alkaline solution and saline nasal lavage on nasopharyngeal viral load in COVID-19.
Batioglu-Karaaltin A; Yigit O; Cakan D; Akgul O; Yigit E; Yilmaz YZ; Cakir KB; Ciftci G; Boyoğlu NS; Cagliyan A; Can E; Dikme O; Hacioglu Y; Balkan II; Enver O; Ozdogan HA
Clin Otolaryngol; 2023 Jul; 48(4):623-629. PubMed ID: 36973223
[TBL] [Abstract][Full Text] [Related]
24. A quadruple blind, randomised controlled trial of gargling agents in reducing intraoral viral load among hospitalised COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial.
Khan FR; Kazmi SMR; Iqbal NT; Iqbal J; Ali ST; Abbas SA
Trials; 2020 Sep; 21(1):785. PubMed ID: 32928313
[TBL] [Abstract][Full Text] [Related]
25. Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
Duvignaud A; Lhomme E; Pistone T; Onaisi R; Sitta R; Journot V; Nguyen D; Peiffer-Smadja N; Crémer A; Bouchet S; Darnaud T; Poitrenaud D; Piroth L; Binquet C; Michel JF; Lefèvre B; Lebeaux D; Lebel J; Dupouy J; Roussillon C; Gimbert A; Wittkop L; Thiébaut R; Orne-Gliemann J; Joseph JP; Richert L; Anglaret X; Malvy D;
Trials; 2020 Oct; 21(1):846. PubMed ID: 33050924
[TBL] [Abstract][Full Text] [Related]
26. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of physiological seawater nasal irrigation for the treatment of children with SARS-CoV-2 Omicron BA.2 variant infection: a randomized controlled trial.
Lin JL; Zhang F; Li YB; Yuan SH; Wu JH; Zhang J; Zhang L; He Y; Chen J; Yin Y
World J Pediatr; 2024 May; 20(5):461-469. PubMed ID: 37691090
[TBL] [Abstract][Full Text] [Related]
29. Ivermectin for preventing and treating COVID-19.
Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930
[TBL] [Abstract][Full Text] [Related]
30. Interferon α-2b spray shortened viral shedding time of SARS-CoV-2 Omicron variant: An open prospective cohort study.
Xu N; Pan J; Sun L; Zhou C; Huang S; Chen M; Zhang J; Zhu T; Li J; Zhang H; Gao Y
Front Immunol; 2022; 13():967716. PubMed ID: 35990674
[TBL] [Abstract][Full Text] [Related]
31. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
[TBL] [Abstract][Full Text] [Related]
32. SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trial.
Tandon M; Wu W; Moore K; Winchester S; Tu YP; Miller C; Kodgule R; Pendse A; Rangwala S; Joshi S;
Lancet Reg Health Southeast Asia; 2022 Aug; 3():100036. PubMed ID: 35784831
[TBL] [Abstract][Full Text] [Related]
33. Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity.
Trunfio M; Salvador E; Gaviraghi A; Audagnotto S; Marinaro L; Motta I; Casciaro R; Ghisetti V; Fava C; Bonora S; Di Perri G; Calcagno A;
Antivir Ther; 2020; 25(6):327-333. PubMed ID: 33506810
[TBL] [Abstract][Full Text] [Related]
34. The Effect of Povidone-Iodine Nasal Spray on Nasopharyngeal SARS-CoV-2 Viral Load: A Randomized Control Trial.
Zarabanda D; Vukkadala N; Phillips KM; Qian ZJ; Mfuh KO; Hatter MJ; Lee IT; Rao VK; Hwang PH; Domb G; Patel ZM; Pinsky BA; Nayak JV
Laryngoscope; 2022 Nov; 132(11):2089-2095. PubMed ID: 34724213
[TBL] [Abstract][Full Text] [Related]
35. One Swab Fits All: Performance of a Rapid, Antigen-Based SARS-CoV-2 Test Using a Nasal Swab, Nasopharyngeal Swab for Nasal Collection, and RT-PCR Confirmation from Residual Extraction Buffer.
Stokes W; Berenger BM; Scott B; Szelewicki J; Singh T; Portnoy D; Turnbull L; Pabbaraju K; Shokoples S; Wong AA; Gill K; Hu J; Tipples G
J Appl Lab Med; 2022 Jun; 7(4):834-841. PubMed ID: 35258088
[TBL] [Abstract][Full Text] [Related]
36. Nasal spray of an IgM-like ACE2 fusion protein HH-120 accelerates SARS-CoV-2 clearance: A single-center propensity score-matched cohort study.
Song R; Chen X; Li B; Zhang H; Guo X; Liu Z; Zou L; Liang X; Lei C; Mao F; Sui J; Li W; Jin R
J Med Virol; 2023 May; 95(5):e28805. PubMed ID: 37227062
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
38. Essentials in saline pharmacology for nasal or respiratory hygiene in times of COVID-19.
Huijghebaert S; Hoste L; Vanham G
Eur J Clin Pharmacol; 2021 Sep; 77(9):1275-1293. PubMed ID: 33772626
[TBL] [Abstract][Full Text] [Related]
39. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
[TBL] [Abstract][Full Text] [Related]
40. Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: A structured summary of a study protocol for an open-label randomized clinical trial.
Hasan MJ; Rumi SKNF; Banu SS; Uddin AKMN; Islam MS; Arefin MK
Trials; 2021 Jan; 22(1):2. PubMed ID: 33397432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
